Your browser doesn't support javascript.
loading
Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial.
Sriranjan, Rouchelle; Zhao, Tian Xiao; Tarkin, Jason; Hubsch, Annette; Helmy, Joanna; Vamvaka, Evangelia; Jalaludeen, Navazh; Bond, Simon; Hoole, Stephen P; Knott, Philip; Buckenham, Samantha; Warnes, Victoria; Bird, Nick; Cheow, Heok; Templin, Heike; Cacciottolo, Paul; Rudd, James H F; Mallat, Ziad; Cheriyan, Joseph.
Afiliação
  • Sriranjan R; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK rfss2@cam.ac.uk.
  • Zhao TX; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Tarkin J; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Hubsch A; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
  • Helmy J; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
  • Vamvaka E; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
  • Jalaludeen N; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
  • Bond S; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Hoole SP; Cardiology, Papworth Hospital NHS Foundation Trust, Cambridge, UK.
  • Knott P; Department of Clinical Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Buckenham S; Department of Clinical Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Warnes V; Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Bird N; Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Cheow H; Department of Nuclear Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Templin H; Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Cacciottolo P; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
  • Rudd JHF; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Mallat Z; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Cheriyan J; Department of Medicine, Division of Experimental Medicine and Immunotherapeutics (EMIT), University of Cambridge, Cambridge, UK.
BMJ Open ; 12(10): e062602, 2022 10 07.
Article em En | MEDLINE | ID: mdl-36207050
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Isquemia Miocárdica / Aterosclerose / Síndrome Coronariana Aguda / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Aspecto: Ethics Limite: Humans Idioma: En Revista: BMJ Open Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Isquemia Miocárdica / Aterosclerose / Síndrome Coronariana Aguda / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Aspecto: Ethics Limite: Humans Idioma: En Revista: BMJ Open Ano de publicação: 2022 Tipo de documento: Article